Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Matthew J. Frigault(Harvard University), Marcela V. Maus(Center for Cancer Research), Mark B. Leick(Massachusetts General Hospital), Lakshmi Nayak(Dana-Farber Cancer Institute), Yi‐Bin Chen(Massachusetts General Hospital), Bryan D. Choi(Harvard University), Zachariah DeFilipp(Harvard University), Lauren S. Riley(Massachusetts General Hospital), Jörg Dietrich(Massachusetts General Hospital), Maria Martinez‐Lage(Universitat Autònoma de Barcelona), Philippe Armand(Harvard University), Chris Panzini(Massachusetts General Hospital), Jeremy S. Abramson(Massachusetts General Hospital), Jennifer L. Crombie(Dana-Farber Cancer Institute), Kathleen Gallagher(Massachusetts General Hospital)
Cited by 237
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
|Nature Biotechnology|2019|724
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions
|Nature Genetics|2010|608